AstraZeneca: Q3 FY 2016 Results (AstraZeneca) - Nov 12, 2016 - Anticipated completion of enrollment in P1 trial (NCT02318394) for advanced malignancies in 2017; Anticipated completion of enrollment in P1 trial (NCT02705482) of durvalumab/tremelimumab + MEDI0562 in advanced malignancies in 2018
Anticipated enrollment status • Oncology
|